Onetone Plus® Cream 20g/0.7oz

4-n-Butylresorcinol 0.3%

USD $33.00

Onetone cream contains 4-n-Butylresorcinol 0.3% aka Rucinol (b resorcinol) 20gm as the main ingredient and showed success in melasma treatment.

It prevents and treats pigmentation with the new Rucinol component. It acts as an antioxidant agent and works on dermal vasodilation.

4-n-butylresorcinol is a derivative of resorcinol and a potent human tyrosinase inhibitor. It is used to decrease skin irritation and is also known to inhibit melanin production.

Brand name: Rucinol
Items:3 - 5 5%
Items:6 - 9 10%
Items:10 + 15%


What is 4-n-Butylresorcinol 0.3% | Rucinol Cream Onetone®

Onetone® is a rare and highly-effective cream among resorcinol products which is manufactured by reputable Micro Labs. The cream contains the main ingredient 4-n-butylresorcinol 0.3% aka b-Resorcinol which showed rapid efficacy and it was well tolerated when used for the treatment of melasma. Also known as Rucinol (4-n-butylresorcinol) is a synthetic compound and is used as a skin whitening agent. A field of application is for the treatment of hyperpigmentation. Hyperpigmentation is caused by a punctually increased production of the body’s own skin pigment melanin, such as lentigo or age spots. 4-n-butylresorcinol, which is a resorcinol derivative that has an inhibitory effect on both tyrosinase and tyrosinase-related protein-1, was introduced in 1995 and it has received increasing attention as a new hypopigmenting agent.

The drug, which was developed in Japan for more than ten years, aims to break down melanin production by inhibiting two enzymes required for melanin synthesis (melanogenesis): tyrosinase and TRP-1. Thus, the melanin production is generally inhibited first, then the production of black melanin, which is responsible for the intense coloration of the pigment spots, specifically blocked.

The result of the double intervention in the hyperpigmentation is a complete discoloration of the pigment spots. The effect of rucinol on melanin production should be about 100 times stronger than that of hydroquinone and more than five times more potent than that of kojic acid.

Melasma treatment with 4-n-butylresorcinol 0.3% (b-resorcinol)

Melasma is an acquired hyperpigmentary disorder that shows a symmetric distribution on sun-exposed areas, and it is predominantly seen on the face. It is common in women of child-bearing age. Sun exposure, oral contraceptive pills, pregnancy, endocrine dysfunction, and a genetic predisposition have all been implicated in the etiology of melasma. Among these, exposure to ultraviolet radiation is thought to be the most important factor.

It is well known that tyrosinase plays key role in melanogenesis as it regulates the rate-limiting step of melanogenesis. Thus, tyrosinase inhibition is one of the major strategies when developing new hypopigmenting agents. The most commercially available hypopigmenting agents include tyrosinase inhibitors as the major active ingredients. Hydroquinone, kojic acid and arbutin are most commonly used and often used in combination with other therapies such as retinoic acid, topical corticosteroids or laser treatment to achieve a synergistic effect.

In 1995, reported that 4-n-Butyl Resorcinol has an inhibitory effect on the melanogenesis of cultured B16 melanoma cells by its direct inhibition of tyrosinase activity, as well as the suppression of tyrosinase synthesis, without inducing any cytotoxicity. Since then, further in vitro studies have demonstrated that 4-n-butylresorcinol inhibits melanin production as well as the activity of both tyrosinase and tyrosinase-related protein-1 (TRP-1).

Despite the increasing attention paid to this agent, only a few clinical trials have demonstrated the hypopigmenting effect of 4-n-butylresorcinol5. In addition, skin irritation can be induced by 4-n-butylresorcinol, which is a resorcinol derivative, and particularly when it is applied in high concentrations. Among the various methods, a lower concentration of 4-n-butylresorcinol can be used to decrease the chance of skin irritation. The aim of this study was to investigate the hypopigmenting efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma.

The results showed that a reduced concentration of 4-n-butylresorcinol can be safely used for the treatment of melasma. Moreover, 4-n-butylresorcinol 0.3% enabled equally effective treatment or even more effective treatment in a shorter duration, as compared with that of the previous studies. In conclusion, 4-n-butylresorcinol 0.3% cream showed significant efficacy as compared with vehicle alone and it showed good tolerability for the treatment of melasma.

Brand name:

Rexsol, Achromin, Noreva, Iklen, Lucinol, Rucinol, Butylresorcinol


Micro Labs Limited

Micro Labs Limited is a multi-faceted healthcare organization with a proficient marketing team, state-of-the-art manufacturing facilities and R&D centers that are at par with international standards. All this, robustly backed by a strong distribution network and path-breaking research work has placed us amongst India’s fast-growing transnational healthcare organizations. Ranking 14th among prescriptions (as per SMSRC May 16' )and 19th in sales (as per AWACS MAT May’16) , Micro’s brand portfolio includes some of the topmost brands in various specialties like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, etc. Amidst our proud achievers is Dolo, an award-winning brand highly prescribed for fever management. The company is also at the forefront of social contribution, striving to be a model corporate citizen in terms of Environmental Protection and Social Initiatives with significant contributions in the areas of education and health. Micro Labs is poised to achieve unparalleled status in the global pharmaceutical industry. Backed by a profound and resolute vision, we now have our eyes set on attaining the $1 billion mark by 2020. The organization’s most important component, however, remains its 9200 dedicated employees. With state-of-the-art facilities and R&D centers designed to international standards, Micro Labs is poised to become a respected global brand in the pharmaceutical field and highlight our nation’s growing reputation. The company today, has 20 marketing divisions catering to leading therapeutic segments such as Cardiology, Diabetology, Pain Management, Dermatology, Veterinary, Neurology, etc. Micro Labs has been in a continuous stage of growth ever since it’s founding years and continues to chart its course as a leader in the pharmaceutical vertical. The company has a presence in over 30 countries with ground level operations in 15 countries, exporting all major dosages on most of the therapeutic segments. We are poised to have a quantum leap in our global operations, with the implementation of our growth strategies. The company currently operates in various countries of Asia, Europe, America & Africa. Micro Labs has already established a strong presence in USA, UK, Russia, Ukraine, Nigeria, French West Africa, East Africa, Myanmar, Philippines, Vietnam, Thailand, Sri Lanka, etc. Latin America, North America, East Europe, Australia, New Zealand, Canada, and North Africa are locations where the company is raising its flag. To complement our vision for global operations, company has established wholly owned subsidiaries in the USA (Micro Labs USA Inc.) , UK (Brown & Burk UK Ltd), Germany (Micro Labs GmbH), Australia (Micro Labs Pty Ltd) and Nigeria (Micro Nova Pharmaceuticals Ind Ltd). The Company has Representative Offices in many other parts of the world (emerging markets). At Micro Labs, we are dedicated to developing top of the line pharmaceutical products, while adhering to the highest quality standards by a world-class research team. The continuous strive for perfection has led us to push our standards of manufacturing by building state-of-the-art facilities. Today these state-of-the-art manufacturing facilities and infrastructure facilitate Micro’s Organic Growth in the regulated markets. The reason why Micro Labs has been able to have a successful run abroad is its world-class manufacturing units. Some of our facilities have been approved by the following regulatory authorities:
  • Food & Drugs Control Administration (FDA)
  • US Medicines & Healthcare products Regulatory Agency (MHRA)
  • UK Health Canada World Health Organisation (WHO)
  • Therapeutic Goods Authority (TGA)
  • Australia Medsafe
  • New Zealand Ministry of Health (MoH)


Diethylene glycol monoethyl ether, Methyl Gluceth 20, Light Liquid Paraffin, Cyclopentasiloxane and Dimethiconal blend, Caprylic Capric Triglyceride, Propylene glycol, Cetostearyl alcohol, Cetyl alcohol, Oxynex ST, Polyacrylate 13, Polyisobutene and polysorbate 20, Glyceryl monostearate, Phenonip methylparaben and ethylparaben and Butylparaben and Propylparaben and Isobutylparaben, 4n butylresorcinol, Disodium EDTA, Butylated hydroxy Toulene, Fragrance, Purified water.


There are no reviews yet.

Be the first to review “Onetone Plus® Cream 20g/0.7oz”

Your email address will not be published. Required fields are marked *